San Diego-centered Viking Therapeutics marked alone as a serious competitor within the weight loss drug market in February immediately after revealing promising knowledge from the mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection and in March the comp